Minerva Neurosciences, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Minerva Neurosciences, Inc. (NERV) reported Net Income (Loss) Available to Common Stockholders, Basic of $16.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-07
- Minerva Neurosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $16.65M.
- Minerva Neurosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$3.26M.
- Minerva Neurosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2015-03-31 was -$6.09M.
- Minerva Neurosciences, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2014-12-31 was -$7.44M.
- Minerva Neurosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2014 was -$56.90M.
- Minerva Neurosciences, Inc. net income (loss) available to common stockholders, basic for fiscal 2013 was -$3.26M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.65M 10-Q · filed 2026-08-07 | -$107.94M 10-Q · filed 2026-08-07 | ||
| 2025-06-30 | -$3.26M 10-Q · filed 2026-08-07 | -$7.01M 10-Q · filed 2026-08-07 | ||
| 2015-03-31 | -$6.09M 10-Q · filed 2015-05-07 | -$13.54M derived: sum of 2 quarters · filed 2015-05-07 | -$40.69M derived: sum of 3 quarters · filed 2015-05-07 | -$60.06M derived: sum of 4 quarters · filed 2015-05-07 |
| 2014-12-31 | -$7.44M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-26 | -$34.60M derived: sum of 2 quarters · filed 2015-03-26 | -$53.96M derived: sum of 3 quarters · filed 2015-03-26 | -$56.90M 10-K · filed 2015-03-26 |
| 2014-09-30 | -$27.16M 10-Q · filed 2014-11-06 | -$46.52M derived: sum of 2 quarters · filed 2014-11-06 | -$49.46M 10-Q · filed 2014-11-06 | -$51.59M derived: sum of 4 quarters · filed 2015-05-07 |
| 2014-06-30 | -$19.37M 10-Q · filed 2014-08-07 | -$22.30M 10-Q · filed 2014-08-07 | -$24.43M derived: sum of 3 quarters · filed 2015-05-07 | -$24.92M derived: sum of 4 quarters · filed 2015-05-07 |
| 2014-03-31 | -$2.94M 10-Q · filed 2015-05-07 | -$5.06M derived: sum of 2 quarters · filed 2015-05-07 | -$5.55M derived: sum of 3 quarters · filed 2015-05-07 | -$5.93M derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | -$2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-26 | -$2.61M derived: sum of 2 quarters · filed 2015-03-26 | -$2.99M derived: sum of 3 quarters · filed 2015-03-26 | -$3.26M 10-K · filed 2015-03-26 |
| 2013-09-30 | -$488.19K 10-Q · filed 2014-11-06 | -$864.15K derived: sum of 2 quarters · filed 2014-11-06 | -$1.14M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | -$375.95K 10-Q · filed 2014-08-07 | -$647.28K 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |